Abstract
The current vaccine against TB, bacille Calmette-Guèrin (BCG) fails to protect against the most prevalent disease form, the pulmonary TB in adults. Thus, it is not a satisfactory vaccine.
Given that T cells are central to protection against TB, future vaccine design should focus on T-lymphocyte populations. Most vaccines do not prevent infection but instead disease, that if they allow establishment of the pathogen in the host but prevent its harmful effects.
The development of synthetic peptide-based immunogens is emerging as a possible approach in human vaccination in the future, as a replacement for conventional vaccines that use killed or attenuated whole microorganisms. The advantages of such synthetic vaccines (high potency, low adverse reactions, low cross-reactivity and high stability) are offset somewhat by the poorer inherent immunogenicity of these constructs. There is a greater need therefore to develop adjuvant/carrier systems to increase the immunogenicity of these newer vaccine candidates.
Keywords: Adjuvants, peptidic vaccine, proteomics, subunit approach, BCG, TB, tuberculosis.
Current Drug Targets
Title:Strategies for Developing Tuberculosis Vaccines: Emerging Approaches
Volume: 14 Issue: 9
Author(s): Adriano Mollica, Azzurra Stefanucci and Roberto Costante
Affiliation:
Keywords: Adjuvants, peptidic vaccine, proteomics, subunit approach, BCG, TB, tuberculosis.
Abstract: The current vaccine against TB, bacille Calmette-Guèrin (BCG) fails to protect against the most prevalent disease form, the pulmonary TB in adults. Thus, it is not a satisfactory vaccine.
Given that T cells are central to protection against TB, future vaccine design should focus on T-lymphocyte populations. Most vaccines do not prevent infection but instead disease, that if they allow establishment of the pathogen in the host but prevent its harmful effects.
The development of synthetic peptide-based immunogens is emerging as a possible approach in human vaccination in the future, as a replacement for conventional vaccines that use killed or attenuated whole microorganisms. The advantages of such synthetic vaccines (high potency, low adverse reactions, low cross-reactivity and high stability) are offset somewhat by the poorer inherent immunogenicity of these constructs. There is a greater need therefore to develop adjuvant/carrier systems to increase the immunogenicity of these newer vaccine candidates.
Export Options
About this article
Cite this article as:
Mollica Adriano, Stefanucci Azzurra and Costante Roberto, Strategies for Developing Tuberculosis Vaccines: Emerging Approaches, Current Drug Targets 2013; 14 (9) . https://dx.doi.org/10.2174/1389450111314090002
DOI https://dx.doi.org/10.2174/1389450111314090002 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy Effects of Chrisotherapeutic Gold Compounds on Prostaglandin E2 Production
Current Drug Targets - Inflammation & Allergy Genetic Diversity of Human SP-A, a Molecule with Innate host Defense and Surfactant-Related Functions; Characteristics, Primary Function, and Significance
Current Pharmacogenomics Withdrawal Notice: EnzyPha, an Engineered Helper Phage Developed to Overcome Most of the Limitations Regarding Filamentous Phage Titration and ELISA Tests
Protein & Peptide Letters Computational Overview of Mycobacterial Thymidine Monophosphate Kinase
Current Pharmaceutical Design Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal Effect of Particle Formulation on Dry Powder Inhalation Efficiency
Current Pharmaceutical Design Rational Design and Evaluation of the Recombinant Multiepitope Protein for Serodiagnosis of Rubella
Current Pharmaceutical Biotechnology Emerging Electrical Biosensors for Detecting Pathogens and Antimicrobial Susceptibility Tests
Current Organic Chemistry Astrocytes and Inflammasome: A Possible Crosstalk in Neurological Diseases
Current Medicinal Chemistry Targeting InhA, the FASII Enoyl-ACP Reductase: SAR Studies on Novel Inhibitor Scaffolds
Current Topics in Medicinal Chemistry Mycobacterium Tuberculosis in New Biologic Era
Current Rheumatology Reviews Editorial [Hot Topic: Tuberculosis (Part 1) (Guest Editor: Douglas B. Lowrie)]
Current Molecular Medicine Methods to Profile the Macromolecular Targets of Small Compounds
Current Topics in Medicinal Chemistry Activity of (-)-Camphene Derivatives Against <i>Mycobacterium tuberculosis</i> in Acidic pH
Medicinal Chemistry Targeting Breast Cancer Cells with G4 PAMAM Dendrimers and Valproic Acid Derivative Complexes
Anti-Cancer Agents in Medicinal Chemistry Smart Biodecorated Hybrid Nanoparticles
Current Bionanotechnology (Discontinued) Patent Selections
Recent Patents on Biotechnology Identifying Key Regulator Genes for Tuberculosis by Differential Co- Expression Analysis of Gene Expression Profiling
Current Bioinformatics